

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



LSHTM Research Online

Anker, SD; Kirwan, BA; van Veldhuisen, DJ; Filippatos, G; Comin-Colet, J; Ruschitzka, F; Lüscher, TF; Arutyunov, GP; Motro, M; Mori, C; +3 more... Roubert, B; Pocock, SJ; Ponikowski, P; (2017) Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. *European journal of heart failure*. ISSN 1388-9842 DOI: <https://doi.org/10.1002/ejhf.823>

Downloaded from: <http://researchonline.lshtm.ac.uk/4256601/>

DOI: <https://doi.org/10.1002/ejhf.823>

Usage Guidelines:

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>

Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis

Stefan D. Anker^{1*}, Bridget-Anne Kirwan^{2,3}, Dirk J. van Veldhuisen⁴, Gerasimos Filippatos⁵, Josep Comin-Colet⁶, Frank Ruschitzka⁷, Thomas F. Lüscher⁷, Gregory P. Arutyunov⁸, Michael Motro⁹, Claudio Mori¹⁰, Bernard Roubert¹⁰, Stuart J. Pocock³, and Piotr Ponikowski¹¹

¹Division of Cardiology and Metabolism—Heart Failure, Cachexia & Sarcopenia; Department of Internal Medicine & Cardiology; DZHK (German Center for Cardiovascular Research); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), at Charité University Medicine, Berlin, Germany; ²Department of Clinical Research, SOCAR Research SA, Nyon, Switzerland; ³Statistical Unit, London School of Hygiene and Tropical Medicine, London, UK; ⁴Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; ⁵Department of Cardiology, Athens University Hospital Attikon, Athens, Greece; ⁶Heart Diseases Biomedical Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain; ⁷Department of Cardiology, University Hospital Zurich, Zurich, Switzerland; ⁸State-Funded Educational Institution of Higher Professional Education The N.I. Pirogov's Russian National Research Medical University, Ministry of Health and Medicine of the Russian Federation, Moscow, Russian Federation; ⁹Department of Cardiology, Sheba Medical Centre, Tel-Aviv University, Tel-Aviv, Israel; ¹⁰Vifor Pharma AG, Glattbrugg, Switzerland; and ¹¹Department of Heart Diseases, Medical University Wroclaw, Wroclaw, Poland

Received 24 November 2016; revised 21 February 2017; accepted 27 February 2017

Aims

Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF) and has been suggested to be associated with poor prognosis. Recently completed double-blind randomised controlled trials (RCTs) studying HF patients with ID have shown improvements in functional capacity, symptoms and quality of life when treated with i.v. ferric carboxymaltose (FCM). This individual patient data meta-analysis investigates the effect of FCM vs. placebo on recurrent hospitalisations and mortality in HF patients with ID.

Methods and results

Individual patient data were extracted from four RCTs comparing FCM with placebo in patients with systolic HF and ID. The main outcome measures were recurrent cardiovascular (CV) hospitalisations and CV mortality. Other outcomes included cause-specific hospitalisations and death. The main analyses of recurrent events were backed up by time-to-first-event analyses. In total, 839 patients, of whom 504 were randomised to FCM, were included. Compared with those taking placebo, patients on FCM had lower rates of recurrent CV hospitalisations and CV mortality [rate ratio 0.59, 95% confidence interval (CI) 0.40–0.88; $P=0.009$]. Treatment with FCM also reduced recurrent HF hospitalisations and CV mortality (rate ratio 0.53, 95% CI 0.33–0.86; $P=0.011$) and recurrent CV hospitalisations and all-cause mortality (rate ratio 0.60, 95% CI 0.41–0.88; $P=0.009$). Time-to-first-event analyses showed similar findings, with somewhat attenuated treatment effects. The administration of i.v. FCM was not associated with an increased risk for adverse events.

Conclusions

Treatment with i.v. FCM was associated with a reduction in recurrent CV hospitalisations in systolic HF patients with ID.

Keywords

Chronic heart failure • Iron deficiency • Ferric carboxymaltose • Individual patient data meta-analysis

*Corresponding author. Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Centre Göttingen (UMG), Robert-Koch-Strasse 40, D-37075 Göttingen, Germany. Tel: +49 551 39 20911, Fax: +49 551 39 91289, Email: s.anker@cachexia.de

Introduction

Despite optimal conventional therapy, many patients with heart failure (HF) remain limited by symptoms, are exercise-intolerant, and are at high risk for repeated hospitalisations and mortality, all of which lead to major public health burdens.^{1,2} Co-morbidities are common in patients with chronic HF, irrespective of the presence of preserved or reduced left ventricular ejection fraction (LVEF), and these may also affect outcomes.^{3,4}

One such co-morbidity is iron deficiency (ID), which is present in approximately 50% of patients with HF.^{5–7} Iron plays a central role in the uptake, transport, storage and metabolism of oxygen, erythropoiesis and cellular immune response.^{8,9} The regulation of systemic iron balance, which is determined by the combination of dietary iron absorption, utilisation and excretion, is essential to maintain fundamental cellular functions, particularly in cells that are characterised by high energy demands, such as skeletal and cardiac myocytes.^{8,10–12} At the cellular level, ID is thought to decrease enzymatic activity of both the Krebs cycle and the respiratory chain in the mitochondria. As a consequence, ID can lead to disturbance in the energetic metabolism of cells.¹³

In HF patients, ID is associated with reduced exercise capacity, impaired quality of life (QoL) and poor prognosis, irrespective of whether anaemia is present or not.^{5,14–18} Two recently published randomised controlled trials (RCTs) investigating patients with systolic HF and ID, which compared the effects of i.v. iron as ferric carboxymaltose (FCM) with placebo, demonstrated important improvements in functional capacity, symptoms and QoL.^{19,20} The clinical and prognostic significance of ID in HF is now well recognised.^{7,21,22} However, the available information on the effects of i.v. iron on morbidity and mortality is limited while no such information is available for the effects of oral iron on these outcomes.²³

The aim of this meta-analysis using individual patient data was to explore the effect of i.v. FCM relative to placebo on recurrent hospitalisations and mortality rates, focusing on recurrent cardiovascular (CV) hospitalisations. Composite outcomes that consider only the first event (i.e. time-to-first-event analyses) are suboptimal for evaluating the progression of chronic diseases such as HF. Hospitalisations for worsening HF are an indication of worsening condition. Taking all such hospitalisations into account is more representative of disease progression and more accurately estimates the effect of treatment on the true burden of disease. It is well known that an increase in such hospitalisations is associated with an increased risk for CV mortality. Any censoring attributable to CV mortality is not independent of the recurrent event process. Recurrent event analysis investigating this outcome must therefore account for the competing risk for CV mortality. Data from all double-blind RCTs comparing i.v. FCM with placebo in patients with systolic HF and ID which were closed by 30 June 2016 are included in this analysis.^{19,20,24,25}

Methods

Study design and inclusion criteria

Four double-blind RCTs investigating the effects of i.v. FCM versus placebo on clinical outcomes, QoL and symptoms in ambulatory after

systolic chronic HF patients with ID that had been closed by 30 June 2016. Data from these four trials, designated FER-CARS-01, FAIR-HF (NCT00520780),¹⁹ EFFICACY-HF (NCT00821717) and CONFIRM-HF (NCT01453608),²⁰ are included in this meta-analysis. The main study design features are shown in *Table 1*. All four studies were approved by the appropriate regulatory authorities and ethics committees, and all patients who participated in the individual RCTs provided written informed consent. The four RCTs were conducted in strict compliance with the guidelines for Good Clinical Practice of the International Council for Harmonisation (ICH GCP) and with the Declaration of Helsinki. The risk for bias from the four RCTs included in this meta-analysis was limited because the four trials were randomised, double-blinded, investigated similar patient populations and used the same iron preparation (i.e. i.v. FCM). A detailed statistical analysis plan (SAP) was prepared a priori for this meta-analysis. All four studies included were designed and undertaken by academic executive committees in conjunction with the sponsor. Authors had full access to all data and had final responsibility for the decision to submit for publication.

Outcome measures

For the purpose of this meta-analysis, the main outcome was pre-defined as the composite of recurrent CV hospitalisations and CV mortality. Other outcomes included the composites of HF hospitalisations and CV mortality, CV hospitalisations and all-cause mortality, and HF hospitalisations and all-cause mortality, in addition to the individual composite components. All outcomes were assessed in recurrent event analyses and backed up by time-to-first-event analyses.

Definition of outcomes

For each RCT, reasons for hospitalisations and cause of mortality were independently adjudicated in a blinded manner by a committee using predefined criteria detailed in an adjudication charter developed for that RCT. The same criteria were used across the four RCTs. The adjudicated outcomes were used in this analysis. All hospitalisations and deaths were adjudicated irrespective of the investigator's reported term. For the purpose of this analysis, all adjudications for 'worsening HF' and 'other CV' were combined for the count of 'any CV hospitalisation'. Cause of death was adjudicated as one of the following: '(worsening of) HF'; 'other CV'; 'non-CV'; 'serious (study) drug reaction', and 'insufficient data to adjudicate'.²⁶ For the purpose of this analysis, safety outcomes focused on the incidence and frequency of reported adverse events (AEs).

Statistical analysis

All analyses used individual patient data and are fully documented in a prespecified SAP. The main outcome analysis was conducted using the full analysis set (FAS). Event rates (including recurrent hospitalisations) were analysed using a log-link negative binomial regression model. The model included fixed covariates of treatment, haemoglobin (Hb) at baseline, region and random effect for study. Length of observation was logged and included as an offset variable. Rate ratios, associated 95% confidence intervals (CIs) and *P*-values were obtained from the model. The interaction term between study and treatment was tested on a separate model to further assess the treatment effect across studies. Statistical heterogeneity across the studies was quantified using the I^2 statistic.

Table 1 Design features of the randomised controlled trials included in this meta-analysis

	FER-CARS-01	FAIR-HF	EFFICACY-HF	CONFIRM-HF
Patient population	Ambulatory, optimally treated, systolic CHF with ID, NYHA class II/III, eGFR < 60 mL/min/1.73 m ²	Ambulatory, optimally treated, systolic CHF with ID, NYHA class II/III	Ambulatory, optimally treated, systolic CHF with ID, NYHA class II/III	Ambulatory, optimally treated, systolic CHF with ID, NYHA class II/III
Randomisation	2:2:1 (FCM:IS:placebo)	2:1 (FCM:placebo)	1:1 (FCM:placebo)	1:1 (FCM:placebo)
Patients, n (FAS) FCM/placebo	30/27 ^a /15	304/155	20/14 ^b	150/151
Comparator	i.v. FCM vs. IS vs. placebo ^c	i.v. FCM vs. placebo ^c	i.v. FCM vs. placebo ^c	i.v. FCM vs. placebo ^c
Study duration	12 weeks	24 weeks	24 weeks	52 weeks
Calculation of iron repletion dose	Ganzoni formula using the mean of two baseline Hb values	Ganzoni formula using the mean of two baseline Hb values	Ganzoni formula using the mean of two baseline Hb values	Determined by baseline Hb values and screening body weight
Correction phase duration (i.e. until iron repletion)	Weekly i.v. injections for minimally 3, maximally 9 weeks	Weekly i.v. injections for maximally 4 weeks	Weekly i.v. injections for minimally 3, maximally 9 weeks	Maximally two i.v. injections over a 6-week period
Correction phase dosing regimen (i.e. until iron repletion)	200 mg/100 mg iron: FCM or placebo	200 mg/100 mg iron: FCM or placebo	200 mg/100 mg iron: FCM or placebo	500 mg/1000 mg iron: FCM or placebo
Maintenance phase	4-weekly 200 mg iron i.v. injection (FCM/placebo) up to 24 weeks after randomisation	4-weekly 200 mg iron i.v. injection (FCM/placebo) up to 12 weeks after randomisation	4-weekly 200 mg iron i.v. injection (FCM/placebo) up to 24 weeks after randomisation	3-monthly 500 mg iron i.v. injection (FCM/placebo) up to 36 weeks after randomisation, if ID still present
Primary endpoint(s)	PGA at week 12 and NYHA class from baseline to week 12	PGA at week 24 and NYHA class from baseline to week 24	Change in 6MWT and NYHA class from baseline to week 24	Change in 6MWT from baseline to week 24

6MWT, 6-minute walk test; CHF, chronic heart failure; eGFR, estimated glomerular filtration rate; FAS, full analysis set; FCM, ferric carboxymaltose; Hb, haemoglobin; ID, iron deficiency; IS, iron sucrose; NYHA, New York Heart Association; PGA, patient global assessment.

Ganzoni formula of total iron deficit [mg]: body weight [kg] × (150 – actual Hb [g/L]) × 0.24 + 500 [mg]. Iron repletion dose, correction of iron deficiency.

^aPatients randomised to i.v. IS (*n* = 27) were not included in this meta-analysis.

^bEFFICACY-HF was discontinued as a result of recruitment issues.

^cPlacebo, i.v. normal saline.

Time-to-first-event analyses were performed using Cox models fitted with fixed effects of treatment, Hb at baseline, region and random study effect. As a sensitivity analysis, a joint frailty model was fitted to jointly examine hospitalisation and death rates. The model assumed Poisson and log-logistic distributions for hospitalisation and time to death, respectively, conditional on the frailty terms, with individual frailties following a gamma distribution. Rates of HF hospitalisation followed a negative binomial distribution, and time to CV mortality followed a Lomax distribution as described by Rogers *et al.*²⁷

Adverse event incidences were presented as the total number of events, patients with at least one event and the event rate per 100 patient-years. The joint frailty model analysis was performed using R Version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria). All other analyses were performed using SAS Version 9.3 (SAS Institute, Inc., Cary, NC, USA).

Results

As of 30 June 2016, four double-blind RCTs comparing FCM with placebo were closed. In total, 844 patients (507 FCM and 337 placebo) had been randomised in the four RCTs. Data for 839 patients (504 FCM and 335 placebo) were included in this analysis

in the FAS, and data for 842 (507 FCM and 335 placebo) were included in the safety set.

Baseline characteristics

Table 2 shows the baseline characteristics and concomitant medications for the pooled dataset. The baseline characteristics were well balanced by treatment allocation, other than New York Heart Association (NYHA) class, in which, compared with the placebo pool, a higher proportion of patients allocated to FCM were in NYHA class III (70% and 61%, respectively, in the FCM and placebo groups).

Follow-up

The overall mean duration of observation was 31 weeks. The proportion of patients in whom study treatment was stopped prematurely was similar in the two groups (9.5% and 10.7% in the FCM and placebo groups, respectively). The mean ± standard deviation (SD) FCM dose needed to correct the ID was 1327 ± 329 mg.

Table 2 Baseline characteristics

Variable	FCM pool (n = 504)	Placebo pool (n = 335)
Demographics		
Baseline age, years, mean ± SD	68.0 ± 10.1	68.3 ± 10.3
Female, n (%)	246 (49%)	169 (50%)
White European ethnicity, n (%)	502 (100%)	334 (100%)
Clinical features/physical findings		
NYHA class, n (%)		
II	146 (29%)	128 (38%)
III	354 (70%)	205 (61%)
IV	4 (1%)	2 (1%)
LVEF, mean ± SD	33.3 ± 6.9	34.5 ± 7.1
BMI, kg/m ² , mean ± SD	27.9 ± 4.7	28.3 ± 5.4
6MWT, distance, m, mean ± SD	277 ± 105	284 ± 106
Cardiovascular risk factors, n (%)		
Hypertension	411 (82%)	283 (84%)
Dyslipidaemia	258 (51%)	182 (54%)
Diabetes mellitus	148 (29%)	93 (28%)
Smoking	145 (29%)	92 (27%)
Medical history, n (%)		
Atrial fibrillation	179 (36%)	126 (38%)
Myocardial infarction	270 (54%)	183 (55%)
Angina pectoris	300 (60%)	194 (58%)
Stroke	46 (9%)	37 (11%)
Coronary revascularisation	116 (23%)	73 (22%)
Laboratory test results		
Hb, g/dL, mean ± SD	12.08 ± 1.34	12.20 ± 1.34
Hb <12 g/dL, n (%)	228 (45%)	142 (42%)
Ferritin, ng/mL, mean ± SD	54.8 ± 52.3	59.9 ± 56.6
Ferritin <100 ng/mL, n (%)	448 (89%)	292 (87%)
TSAT, %, mean ± SD	18.5 ± 14.1	17.5 ± 8.5
TSAT ≤20%, n (%)	338 (67%)	220 (66%)
eGFR (CKD-EPI), mL/min/1.73 m ² , mean ± SD	62.9 ± 21.3	63.1 ± 22.6
eGFR <60 mL/min/1.73 m ² , n (%)	216 (43%)	156 (47%)
Concomitant treatments, n (%)		
Diuretics	465 (92%)	307 (92%)
ACE inhibitor or angiotensin receptor blocker	473 (93%)	313 (93%)
Beta-blocker	438 (86%)	294 (88%)
Aldosterone antagonists	278 (55%)	174 (52%)
Digitalis glycoside	94 (19%)	80 (24%)
Warfarin	52 (10%)	37 (11%)
Lipid-lowering therapy	272 (54%)	195 (58%)

6MWT, 6-minute walk test; ACE, angiotensin-converting enzyme; BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration formula; eGFR, estimated glomerular filtration rate; FCM, ferric carboxymaltose; Hb, haemoglobin; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SD, standard deviation; TSAT, transferrin saturation.

The overall mean ± SD cumulative FCM dose administered was 1679 ± 522 mg.

Outcomes

Table 3 and Figure 1 show the results for recurrent hospitalisations and mortality. Compared with placebo, FCM significantly reduced rates of recurrent CV hospitalisations and CV mortality (rate ratio 0.59, 95% CI 0.40–0.88; $P=0.009$), recurrent HF hospitalisations and CV mortality (rate ratio 0.53, 95% CI 0.33–0.86; $P=0.011$),

recurrent CV hospitalisations and all-cause mortality (rate ratio 0.60, 95% CI 0.41–0.88; $P=0.009$), and recurrent HF hospitalisations and all-cause mortality (rate ratio 0.54, 95% CI 0.34–0.87; $P=0.011$). Figure 2 depicts the extent of the contribution of each trial to the overall estimate for the main outcome of recurrent CV hospitalisations and CV mortality.

Table 4 shows the data for the time-to-first-event analyses. Compared with those in the placebo group, the occurrence of HF hospitalisations or CV mortality was less frequent in patients assigned to FCM (hazard ratio 0.55, 95% CI 0.35–0.88; $P=0.012$), as was that of HF hospitalisations or all-cause mortality (hazard ratio 0.56, 95% CI 0.36–0.88; $P=0.013$). Kaplan–Meier plots for the time-to-first-event analysis are shown in the supplementary material online (Figure S1).

The median duration for a HF hospitalisation was 10 days (minimum: 3 days; maximum: 31 days) for patients randomised to FCM and 12 days (minimum: 1 day; maximum: 165 days) for patients randomised to placebo.

Prespecified subgroup analysis

Figure 3 depicts the prespecified subgroup analyses performed for the key subgroups (in tertiles) [Hb, serum ferritin and transferrin saturation (TSAT)] for the composite outcomes of recurrent CV hospitalisations and CV mortality, recurrent HF hospitalisations and CV mortality, and recurrent CV hospitalisations and all-cause mortality. A substantially lower effect was observed for the three composite outcomes in the subgroup with TSAT of ≥20.1%.

Safety reporting

The proportion of patients who experienced at least one AE (serious or non-serious) was similar in both treatment groups, with incidence rates of 105.4 and 95.8 per 100 patient-years at risk in the FCM and placebo groups, respectively. The proportions of patients who withdrew from study treatment as a result of an AE were 6.3% in patients allocated to FCM and 10.1% in patients allocated to placebo (Table 5). No serious or severe hypersensitivity reactions were reported and the nature, type, intensity and frequency of AEs were similar between the two treatment groups across the four RCTs.

Sensitivity analysis

A random-effects model analysis was performed and the overall rate ratios were consistent with the direction and size of those calculated by the fixed-effects model. The leave-one-out cross-validation method was used on the model to investigate the validity and robustness of the meta-analysis. The results of this validation did not change the overall results.

Discussion

The main finding of the present meta-analysis is that treatment with i.v. iron (FCM) is associated with lower rates of recurrent CV hospitalisations and CV mortality in ambulatory, stable, systolic

Table 3 Recurrent event outcomes

Outcomes	Total events, n (incidence per 100 patient-years of follow-up)		RR (95% CI)	P-value
	FCM pool (n = 504)	Placebo pool (n = 335)		
CV hospitalisations and CV mortality	69 (23.0)	92 (40.9)	0.59 (0.40–0.88)	0.009
HF hospitalisations and CV mortality	39 (13.0)	60 (26.7)	0.53 (0.33–0.86)	0.011
CV hospitalisations and all-cause mortality	71 (23.7)	94 (41.8)	0.60 (0.41–0.88)	0.009
HF hospitalisations and all-cause mortality	41 (13.7)	62 (27.6)	0.54 (0.34–0.87)	0.011
All-cause hospitalisations and all-cause mortality	108 (36.1)	118 (52.5)	0.73 (0.52–1.01)	0.060
HF hospitalisations	22 (7.3)	43 (19.1)	0.41 (0.23–0.73)	0.003
CV hospitalisations	52 (17.4)	75 (33.3)	0.54 (0.36–0.83)	0.004
All-cause hospitalisations	89 (29.7)	99 (44.0)	0.71 (0.50–1.01)	0.056

CI, confidence interval; CV, cardiovascular; FCM, ferric carboxymaltose; HF, heart failure; RR, rate ratio.




Figure 1 Recurrent event analyses for (A) cardiovascular (CV) hospitalisations and CV mortality, (B) heart failure (HF) hospitalisations and CV mortality, and (C) CV hospitalisations and all-cause mortality. CI, confidence interval; FCM, ferric carboxymaltose.

HF patients with ID. Treatment with i.v. FCM was not associated with an increased risk for AEs compared with placebo. This is the first meta-analysis using individual patient data obtained from four closed RCTs using i.v. iron (FCM) in HF populations with ID.

Recent meta-analyses investigating the effects of treatment with i.v. iron on hospitalisations and mortality using published data showed similar benefits of iron treatment with respect to HF hospitalisations and the combination of HF hospitalisations and death.^{28–31}

However, the criteria used to determine ID differed between the RCTs included, as did the i.v. iron therapy and doses used.^{28–31} Furthermore, the use of erythropoietin-stimulating agents (ESAs) was allowed in several of these RCTs. Only one of the meta-analyses analysed recurrent HF hospitalisations.²⁹

In the present meta-analysis, we included individual patient data from four RCTs that used the same iron preparation (i.v. FCM). The patient populations included were similar and the same criteria were used to determine the presence of ID across the four RCTs.




Figure 2 Rate ratios for cardiovascular hospitalisations and cardiovascular mortality for the individual randomised controlled trials included in this meta-analysis. CI, confidence interval; FCM, ferric carboxymaltose.

Table 4 Time-to-first-event outcomes

Outcomes	Patients with event, n (incidence per 100 patient-years at risk)		HR (95% CI)	P-value
	FCM pool (n = 504)	Placebo pool (n = 335)		
CV hospitalisation or CV mortality	55 (18.4)	59 (26.2)	0.70 (0.48–1.02)	0.062
HF hospitalisation or CV mortality	32 (10.7)	44 (19.6)	0.55 (0.35–0.88)	0.012
CV hospitalisation or all-cause mortality	57 (19.0)	61 (27.1)	0.70 (0.49–1.02)	0.060
HF hospitalisation or all-cause mortality	34 (11.4)	46 (20.4)	0.56 (0.36–0.88)	0.013
All-cause hospitalisation or all-cause mortality	81 (27.0)	75 (33.3)	0.81 (0.59–1.12)	0.199
HF hospitalisation	19 (6.3)	34 (15.1)	0.42 (0.24–0.74)	0.003
CV hospitalisation	43 (14.4)	52 (23.1)	0.61 (0.40–0.91)	0.017
All-cause hospitalisation	68 (22.7)	67 (29.8)	0.75 (0.53–1.06)	0.099
CV mortality	17 (5.7)	17 (7.6)	0.84 (0.43–1.66)	0.620
All-cause mortality	19 (6.3)	19 (8.4)	0.84 (0.44–1.61)	0.604

CI, confidence interval; CV, cardiovascular; FCM, ferric carboxymaltose; HF, heart failure; HR, hazard ratio.

This allowed for a more accurate, granular and robust assessment of the relative effects of the administration of i.v. iron (i.e. FCM) on recurrent hospitalisations and mortality compared with the other recently performed meta-analyses.^{28–31}

Although ID is recognised as a common and important co-morbidity in HF, neither screening for ID nor its subsequent treatment are yet part of the routine standard of care in this patient population. There is therefore a need to increase awareness among general practitioners and cardiologists to both identify and subsequently initiate treatment with i.v. iron (FCM), which has been shown to have a positive impact on clinical outcome, physical performance and QoL in this patient population.^{19–21} This is reflected in the recently updated European Society of Cardiology (ESC) HF Guidelines 2016, which recommend screening

for ID in HF patients (recommendation IC) and, in addition, to consider using i.v. FCM in symptomatic systolic HF patients with ID (recommendation IIaA).²¹

There is limited evidence of clinically meaningful benefits using oral iron preparations to treat ID in HF patients. Oral iron is both poorly absorbed and badly tolerated because of adverse gastrointestinal effects, particularly in patients with chronic diseases, such as HF.³² There are also limited data concerning the efficacy and safety of other i.v. iron preparations in the treatment of ID in HF patients. Only three small controlled studies have investigated the efficacy and safety of i.v. iron sucrose in systolic HF patients with ID.^{33–35} The iron sucrose trials enrolled 23, 11 and 20 patients, respectively, and the results showed initial benefits in improving symptoms, QoL and functional capacity. A larger RCT




Figure 3 Subgroup analyses for (A) recurrent cardiovascular hospitalisations and cardiovascular mortality, (B) recurrent heart failure hospitalisations and cardiovascular mortality, and (C) recurrent cardiovascular hospitalisations and all-cause mortality. CI, confidence interval; FCM, ferric carboxymaltose; TSAT, transferrin saturation.

Table 5 Investigator-reported adverse events (AEs)

Safety reporting	FCM pool (n = 507)		Placebo pool (n = 335)	
	Patients with event, n (%)	Incidence/100 patient-years at risk	Patients with event, n (%)	Incidence/100 patient-years at risk
AEs	317 (62.5%)	105.4	215 (64.2%)	95.8
Serious AEs	86 (17.0%)	28.6	79 (23.6%)	35.2
AEs leading to study drug withdrawal	32 (6.3%)	10.6	34 (10.1%)	15.1
Study drug-related AEs	50 (9.9%)	16.6	20 (6.0%)	8.9
Serious drug-related AEs	0	0	1 (0.3%)	0.4
Study drug-related AEs leading to study drug withdrawal	7 (1.4%)	2.3	3 (0.9%)	1.3

FCM, ferric carboxymaltose.

[Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure (IRONOUT)] recently reported that oral iron did not replenish depleted iron stores and, as a consequence, did not improve peak VO₂ or any clinically relevant outcomes in HF with reduced ejection fraction (HFrEF) patients with ID.³⁶ The authors concluded that the IRONOUT results do not support the use of oral iron supplementation in HFrEF patients with ID.³⁶

The current treatment recommendations for HF include the prescription of beta-blockers, ACE inhibitors and/or angiotensin

receptor blockers, and diuretics. These treatments play a critical role in the management of HF. Just over 90% of patients included in the four RCTs analysed in this meta-analysis were prescribed at least one of these drugs and could thus be considered as being 'optimally treated'. However, despite the optimisation of HF treatments in systolic HF, post-discharge mortality and readmission rates for HF in patients with HF remain unacceptably high. This confirms that other HF co-morbidities should be considered in the process of defining overall treatment strategies for HF patients.²¹

In the exploratory pre-planned subgroup analysis, the reductions in recurrent CV hospitalisations and CV mortality, in recurrent HF hospitalisations and CV mortality, and in recurrent CV hospitalisations and all-cause mortality in the FCM vs. placebo groups were larger in patients with TSAT in the two lower tertiles (i.e. TSAT of <12.7% and TSAT of 12.7–20.1%). Although these findings should be interpreted with caution, they do warrant the targeting of further research to better understand the role of TSAT in the definition of ID. Such research is currently ongoing.

The FAIR-HF¹⁹ and CONFIRM-HF²⁰ trials contributed approximately 90% of the total number of patients included in our meta-analysis. A sensitivity analysis was performed and showed that the overall rate ratios were consistent with the direction and size of those calculated by the fixed-effects model. The results of our meta-analysis are limited by sample size, number of deaths and follow-up duration in the clinical trials included in this analysis, in addition to the relatively small number of outcomes observed in the control group. We also recognise that subgroup analyses in meta-analyses pose methodological challenges and should be viewed with caution.

Meta-analyses may provide useful information concerning treatment-related outcomes and may guide future research. However, prospective RCTs remain the gold standard method and are considered to provide the strongest and most robust evidence concerning an intervention. Four large (>1000 patients in each trial) RCTs evaluating the effects of i.v. iron on mortality and hospitalisations in differing HF populations are being set up or are currently recruiting. In three of these RCTs [FAIR-HF2 (NCT03036462), AFFIRM-AHF (NCT02937454), HEART-FID (NCT03037931)], patients will be randomised to either i.v. FCM or placebo, and in the fourth RCT [IRONMAN (NCT02642562)] patients will be randomised to either i.v. iron isomaltoside or placebo. The results of all these trials are expected within the next 5 years.

Conclusions

The results of this individual patient data meta-analysis show that treatment of ID with i.v. FCM in ambulatory systolic HF patients with ID may decrease recurrent CV hospitalisations. These findings suggest that i.v. iron therapy may potentially represent a beneficial addition to the standard medical management of HF. An adequately powered RCT is needed to confirm these findings.

Supplementary Information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Kaplan–Meier plots for time-to-first-event analyses.

Acknowledgements

We would like to thank Marie Watissee, Ben Hartley and Lynette Salkeld (Veramed Ltd) and Patrick Moneuse (Vifor Pharma AG) for contributions to the statistical analysis. We also thank Emilie Perrin (SOCAR Research SA) for the provision of editorial assistance with the preparation of the tables, figures and references.

Funding

This work was supported by Vifor Pharma AG, Glattbrugg, Switzerland.

Conflict of interest: S.D.A. received personal fees from Vifor Pharma, Bayer, Servier, Novartis, Cardioentis, Janssen, ZS Pharma and Relypsa, and research grants from Abbott Vascular and Vifor Pharma. D.J.v.V. received board membership fees from Vifor Pharma. G.F. received committee fees from Vifor Pharma, Bayer, Servier, Novartis and Cardioentis. J.C.-C., F.R., G.P.A., M.M. and S.J.P. received personal fees from Vifor Pharma. C.M. and B.R. are employees of Vifor Pharma. P.P. received personal fees from Vifor Pharma, Servier, Novartis and Cardioentis. B.-A.K. and T.F.L. declare no competing interests.

References

- Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. *Circulation* 2013;**127**:e6–e245.
- Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo LM, Drozd J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). *Eur J Heart Fail* 2013;**15**:808–817.
- Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. *Heart* 2007;**93**:665–671.
- van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. *J Am Coll Cardiol* 2013;**61**:1498–1506.
- Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. *Am Heart J* 2013;**165**:575–582.
- Yeo TJ, Yeo PS, Ching-Chiew WR, Ong HY, Leong KT, Jaufeerally F, Sim D, Santhanakrishnan R, Lim SL, Chan MY, Chai P, Low AF, Ling LH, Ng TP, Richards AM, Lam CS. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. *Eur J Heart Fail* 2014;**16**:1125–1132.
- von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. *Nat Rev Cardiol* 2015;**12**:659–669.
- Cairo G, Bernuzzi F, Recalcati S. A precious metal: iron, an essential nutrient for all cells. *Genes Nutr* 2006;**1**:25–39.
- Haas JD, Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. *J Nutr* 2001;**131**:676S–688S.
- Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. *Eur Heart J* 2013;**34**:816–829.
- Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. *Eur J Heart Fail* 2017;**19**:522–530.
- Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA. The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. *Eur J Heart Fail* 2016;**18**:762–773.
- Oexle H, Gnaiger E, Weiss G. Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation. *Biochim Biophys Acta* 1999;**1413**:99–107.
- Comin-Colet J, Enjuanes C, Gonzalez G, Torrens A, Cladellas M, Merono O, Ribas N, Ruiz S, Gomez M, Verdu JM, Bruguera J. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. *Eur J Heart Fail* 2013;**15**:1164–1172.

15. Enjuanes C, Klip IT, Bruguera J, Cladellas M, Ponikowski P, Banasiak W, van Veldhuisen DJ, van der Meer P, Jankowska EA, Comin-Colet J. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. *Int J Cardiol* 2014;**174**:268–275.
16. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadziejka L, von Haehling S, Doehner W, Banasiak W, Polonski L, Filippatos G, Anker SD, Ponikowski P. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. *J Card Fail* 2011;**17**:899–906.
17. Okonko DO, Mandal AK, Missouri CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. *J Am Coll Cardiol* 2011;**58**:1241–1251.
18. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. *Nat Rev Cardiol* 2011;**8**:485–493.
19. Anker SD, Comin CJ, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med* 2009;**361**:2436–2448.
20. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J* 2015;**36**:657–668.
21. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;**18**:891–975.
22. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;**62**:e147–e239.
23. Rocca HP, Crijns HJ. Iron i.v. in heart failure: ready for implementation? *Eur Heart J* 2015;**36**:645–647.
24. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Mori C, von Eisenhart RB, Pocock S, Poole-Wilson PA, Ponikowski P. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. *Eur J Heart Fail* 2009;**11**:1084–1091.
25. Arutyunov GP, Bylova NA, Ivleva AY, Kobalava ZD. The safety of intravenous (IV) ferric carboxymaltose versus IV iron sucrose in patients with chronic heart failure (CHF) and chronic kidney disease (CKD) with iron deficiency (ID) [abstract]. *Eur J Heart Fail* 2009;**8** (Suppl. 2):ii71.
26. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. *ESC Heart Fail* 2014;**1**:52–58.
27. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon SD, Swedberg K, Yusuf S. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. *Eur J Heart Fail* 2014;**16**:33–40.
28. Avni T, Leibovici L, Gafer-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. *Eur J Heart Fail* 2012;**14**:423–429.
29. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. *Eur J Heart Fail* 2016;**18**:786–795.
30. Kapoor M, Schleintz MD, Gemignani A, Wu WC. Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis. *Cardiovasc Hematol Disord Drug Targets* 2013;**13**:35–44.
31. Qian C, Wei B, Ding J, Wu H, Wang Y. The efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: a systematic review and meta-analysis. *Can J Cardiol* 2016;**32**:151–159.
32. McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? *Eur J Heart Fail* 2015;**17**:248–262.
33. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. *Int J Cardiol* 2013;**168**:3439–3442.
34. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouri CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. *J Am Coll Cardiol* 2008;**51**:103–112.
35. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. *J Am Coll Cardiol* 2007;**50**:1657–1665.
36. Lewis GD, Semigran MJ, Givertz MM, Malhotra R, Anstrom KJ, Hernandez AF, Shah MR, Braunwald E. Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure. *Circ Heart Fail* 2016;**9**:pii: e000345.